A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus
Open Access
- 17 November 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (12) , e0151421
Abstract
Fluoroquinolones—the only clinically used DNA gyrase inhibitors—are effective against tuberculosis (TB) but are in limited clinical use for nontuberculous mycobacteria (NTM) lung infections due to intrinsic drug resistance. We sought to test alternative DNA gyrase inhibitors for anti-NTM activity. Mycobacterium tuberculosis Gyrase Inhibitors (MGIs), a subclass of Novel Bacterial Topoisomerase Inhibitors (NBTIs), were recently shown to be active against the tubercle bacillus.Keywords
Funding Information
- HHS | National Institutes of Health (R01AI132374)
- Cystic Fibrosis Foundation (DICK17XX00)
This publication has 61 references indexed in Scilit:
- Draft Genome Sequence of Mycobacterium abscessus subsp. bolletii BDTJournal of Bacteriology, 2012
- Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerasesBioorganic & Medicinal Chemistry Letters, 2011
- Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerasesBioorganic & Medicinal Chemistry Letters, 2011
- Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm (41) and rrl SequencingAntimicrobial Agents and Chemotherapy, 2011
- A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacyNature Communications, 2010
- A Novel Gene,erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates ofMycobacterium abscessusbut Is Absent fromMycobacterium chelonaeAntimicrobial Agents and Chemotherapy, 2009
- Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II TopoisomerasesAntimicrobial Agents and Chemotherapy, 2008
- Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: Synthesis and preliminary SAR analysisBioorganic & Medicinal Chemistry Letters, 2007
- Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strainsBioorganic & Medicinal Chemistry Letters, 2007
- Genes Required for Intrinsic Multidrug Resistance in Mycobacterium aviumAntimicrobial Agents and Chemotherapy, 2004